COVID-19 Sürecinde Deliryum Olgu Sunumu ve Demansın Literatür Taraması

Year 2020, , 71 - 75, 30.11.2020

Meryem Tuba Sönmez , Tülin Aktürk , Hikmet Saçmacı

https://doi.org/10.18678/dtfd.782594

Abstract

Koronavirüs doğrudan sinir sistemini enfekte etmesinin yanı sıra kronik nörolojik hastalığı olanlarda mevcut nörolojik hastalığın daha kötü seyretmesine neden olabilmektedir. Altmış beş yaş üstünde en sık görülen kronik nörolojik hastalık olan demans hastaları sosyal izolasyon sürecinde hastalıklarının takip ve tedavisi açısından ciddi zorluklar yaşamaktadır. Bununla birlikte koronavirüs hastalığı 2019 (coronavirus disease 2019, COVID-19)’un sebep olduğu risk faktörleri nedeniyle deliryuma girmeleri de kolaylaşmıştır. Bu risk faktörleri sosyal izolasyon, hareketsizlik, yoğun stresin yanı sıra virüsün merkezi sinir sistemine direk invazyonu, inflamatuar sitokinlerin etkisi, kullanılan sedatif ilaçların etkisi ve eşlik eden hastalıkların ikincil etkileri olarak sıralanabilir. Bu yazı bir olgu sunumu eşliğinde, demans hastalarının pandemi sürecinde yaşadıkları problemler ve çözümleri üzerine bir değerlendirme sunmaktadır.

Keywords

COVID-19, demans, deliryum

A Case Report of Delirium and Literature Review of Dementia in COVID-19 Process

Abstract

Coronavirus directly infects the nervous system and may cause the course of the existing neurological disease to get worse in those with a chronic neurological disease. People with dementia, which is the most common chronic neurological disease over 65 years old, have serious difficulties in terms of follow-up and treatment of their diseases in the social isolation process. However, due to the risk factors caused by coronavirus disease 2019 (COVID-19), it has become easier for them to go into delirium. These risk factors can be listed as social isolation, inactivity, intense stress, as well as direct invasion of the virus to the central nervous system, the effect of inflammatory cytokines, the effect of sedative drugs used and the effect that develops secondary to other accompanying diseases. This paper provides an assessment regarding the problems experienced by dementia patients in the pandemic process, and their solutions, accompanied by a case presentation.

Keywords

COVID-19, dementia, delirium

References

• Wang H, Li T, Barbarino P, Gauthier S, Brodaty H, Molinuevo JL, et al. Dementia care during COVID-19. Lancet. 2020;395(10231):1190-1.
• Atkins JL, Masoli JAH, Delgado J, Pilling LC, Kuo CL, Kuchel GA, et al. Preexisting comorbidities predicting COVID-19 and mortality in the UK biobank community cohort. J Gerontol A Biol Sci Med Sci. 2020;75(11):2224-30.
• Kim H, Jhoo JH, Jang JW. The effect of telemedicine on cognitive decline in patients with dementia. J Telemed Telecare. 2017;23(1):149-54.
• Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683-90.
• Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis. 2020;94:55-8.
• Aghagoli G, Gallo Marin B, Katchur NJ, Chaves-Sell F, Asaad WF, Murphy SA, et al. Neurological involvement in COVID-19 and potential mechanisms: A review. Neurocrit Care. 2020;[Epub ahead of print]. doi: 10.1007/s12028-020-01049-4.
• Nath A. Neurologic complications of coronavirus infections. Neurology. 2020;94(19):809-10.
• Abiodun OA, Ola MS. Role of brain renin angiotensin system in neurodegeneration: An update. Saudi J Biol Sci. 2020;27(3):905-12.
• Almeida-Santos AF, Kangussu LM, Campagnole-Santos MJ. The renin-angiotensin system and the neurodegenerative diseases: a brief review. Protein Pept Lett. 2017;24(9):841-53.
• Kuo C-L, Pilling LC, Atkins JL, Masoli JAH, Delgado J, Kuchel GA, et al. APOE e4 genotype predicts severe COVID-19 in the UK Biobank community cohort. J Gerontol A Biol Sci Med Sci. 2020;75(11):2231-2.
• Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278(16):1349-56.
• Kotfis K, Williams Roberson S, Wilson JE, Dabrowski W, Pun BT, Ely EW. COVID-19: ICU delirium management during SARS-CoV-2 pandemic. Crit Care. 2020;24(1):176.
• Browne J, Edwards DA, Rhodes KM, Brimicombe DJ, Payne RA. Association of comorbidity and health service usage among patients with dementia in the UK: a population-based study. BMJ Open. 2017;7(3):e012546.
• Foley NC, Affoo RH, Martin RE. A systematic review and meta-analysis examining pneumonia-associated mortality in dementia. Dement Geriatr Cogn Disord. 2015;39(1-2):52-67.
• Fotuhi M, Mian A, Meysami S, Raji CA. Neurobiology of COVID-19. J Alzheimers Dis. 2020;76(1):3-19.
• Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62.
• Brown EE, Kumar S, Rajji TK, Pollock BG, Mulsant BH. Anticipating and mitigating the impact of COVID-19 pandemic on Alzheimer's disease and related dementias. Am J Geriatr Psychiatry. 2020;28(7):712-21.
• Ford AH. Preventing delirium in dementia: Managing risk factors. Maturitas. 2016;92:35-40.
• Davies SJ, Burhan AM, Kim D, Gerretsen P, Graff-Guerrero A, Woo VL, et al. Sequential drug treatment algorithm for agitation and aggression in Alzheimer's and mixed dementia. J Psychopharmacol. 2018;32(5):509-23.
• Zambrelli E, Canevini M, Gambini O, D'Agostino A. Delirium and sleep disturbances in COVID-19: a possible role for melatonin in hospitalized patients? Sleep Med. 2020;70:111.
• Ferini-Strambi L, Salsone M. COVID-19 and neurological disorders: are neurodegenerative or neuroimmunological diseases more vulnerable? J Neurol. 2020;[Epub ahead of print]. doi: 10.1007/s00415-020-10070-8.
• Boots L, de Vugt ME, Van Knippenberg R, Kempen GI, Verhey FR. A systematic review of Internet‐based supportive interventions for caregivers of patients with dementia. Int J Geriatr Psychiatry. 2014;29(4):331-44.
• Moo LR, Gately ME, Jafri Z, Shirk SD. Home-based video telemedicine for dementia management. Clin Gerontol. 2020;43(2):193-203.
• Cuffaro L, Di Lorenzo F, Bonavita S, Tedeschi G, Leocani L, Lavorgna L. Dementia care and COVID-19 pandemic: a necessary digital revolution. Neurol Sci. 2020;41(8):1977-9.
• Hsu TJ, Tsai HT, Hwang AC, Chen LY, Chen LK. Predictors of non-pharmacological intervention effect on cognitive function and behavioral and psychological symptoms of older people with dementia. Geriatr Gerontol Int. 2017;17(Suppl 1):28-35.
• Acar T, Acıman Demirel E, Afşar N, Akçalı A, Akman Demir G, Alagöz AN, et al. The COVID-19 from neurological overview. Turk J Neurol. 2020;26(2):58-108.
• Ousset PJ, Vellas B. Viewpoint: Impact of the COVID-19 outbreak on the clinical and research activities of memory clinics: An Alzheimer’s disease center facing the COVID-19 crisis. J Prev Alz Dis. 2020;3(7):197-8.
• Alzheimer's Disease Research Enterprise in the Era of COVID-19/SARS-CoV-2. Alzheimers Dement. 2020;16(4):587-8.
• Balli N, Kara E, Demirkan K. The another side of COVID‐19 in Alzheimer’s disease patients: drug‐drug interactions. Int J Clin Pract. 2020;74(10):e13596.
• Korczyn AD. Dementia in the COVID-19 period. J Alzheimers Dis. 2020;75(4):1071-2.